FdaApplication
NDA 216203
Identifiers
- fda_app_no: NDA216203
Properties
| Property | Value |
|---|---|
| applicant_name | LEXICON PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2023-05-26 |
Revenue by product
INPEFA
| Period | Revenue |
|---|---|
| Q1 2026 | $1.1M |
| Q3 2025 | $1.0M |
| Q1 2025 | $1.3M† |
| Q4 2024 | $26.6M† |
| Q3 2024 | $1.8M† |
| Q2 2024 | $1.6M† |
| Q1 2024 | $1.1M† |
| Q4 2023 | $0.7M† |
| Q3 2023 | $0.2M† |
| Q2 2023 | $0.3M† |
| Q1 2023 | $0.0M† |
| Q4 2022 | $0.0M† |
| Q3 2022 | $0.0M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| INPEFA | SOTAGLIFLOZIN | 200MG | TABLET;ORAL |
| INPEFA | SOTAGLIFLOZIN | 400MG | TABLET;ORAL |
2 products